E!11411, PILLOXA, Pilloxa AB
| Reference number | |
| Coordinator | Pilloxa AB |
| Funding from Vinnova | SEK 4 550 127 |
| Project duration | September 2020 - November 2022 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
Fulfillment of the purpose and goals of the project has been partially fulfilled as the ASTORIA study under WP2 has not yet been completed due to delays during Covid. The remaining work packages have been completed- Based on the changed market situation with the corona pandemic, Pilloxa´s value proposition, technology and business model have been updated to reflect this, which has led to a very good response from prospective customers. Pilloxa is also in the process of being acquired by another company in the final stage of the project period.
Expected long term effects
The result of the project has been multilateral; new and improved products at Pilloxa together with a new value proposition and business model with great potential for success. An unexpected positive side effect of Covid has been the acceptance of healthcare and pharmaceutical companies for the value and role that digital health now plays and will have to play in the future - which we have done our best to exploit to the maximum. Initial feedback from patients in the study shows that they take their medications significantly better now compared to before.
Approach and implementation
The layout and execution of the project changed a lot due to Covid. Digital meetings with all stakeholders, patients who could not get to hospital due to restrictions and Pilloxa education of healthcare staff and patients. Pilloxa became a remote company for most of the project period, which also meant that some of the resources that we initially thought would be in-house as employees in the second part of the project period were transferred to remote consultants that will be reflected in the budget.